Published in Neuropsychobiology on May 08, 2010
Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. Lancet (2016) 1.61
Antidepressant-like responses to lithium in genetically diverse mouse strains. Genes Brain Behav (2011) 1.01
Long-term lithium treatment in bipolar disorder is associated with longer leukocyte telomeres. Transl Psychiatry (2013) 0.96
Molecular actions and clinical pharmacogenetics of lithium therapy. Pharmacol Biochem Behav (2014) 0.94
Genetic research into bipolar disorder: the need for a research framework that integrates sophisticated molecular biology and clinically informed phenotype characterization. Psychiatr Clin North Am (2010) 0.93
Increased ratio of anti-apoptotic to pro-apoptotic Bcl2 gene-family members in lithium-responders one month after treatment initiation. Biol Mood Anxiety Disord (2012) 0.93
Assessment of Response to Lithium Maintenance Treatment in Bipolar Disorder: A Consortium on Lithium Genetics (ConLiGen) Report. PLoS One (2013) 0.88
Genetic influences on response to mood stabilizers in bipolar disorder: current status of knowledge. CNS Drugs (2013) 0.83
Interaction networks of lithium and valproate molecular targets reveal a striking enrichment of apoptosis functional clusters and neurotrophin signaling. Pharmacogenomics J (2011) 0.81
Predictors of lithium response in bipolar disorder. Ther Adv Chronic Dis (2011) 0.80
Genome-wide association study of 40,000 individuals identifies two novel loci associated with bipolar disorder. Hum Mol Genet (2016) 0.79
Response to treatment in bipolar disorder. Curr Opin Psychiatry (2011) 0.78
Development of a bipolar disorder biobank: differential phenotyping for subsequent biomarker analyses. Int J Bipolar Disord (2015) 0.77
Circadian biomarkers in patients with bipolar disorder: promising putative predictors of lithium response. Int J Bipolar Disord (2014) 0.76
Response to lithium in bipolar disorder: clinical and genetic findings. ACS Chem Neurosci (2014) 0.76
Pharmacogenomics of mood stabilizers in the treatment of bipolar disorder. Hum Genomics Proteomics (2010) 0.75
Pharmacogenomics in the treatment of mood disorders: Strategies and Opportunities for personalized psychiatry. EPMA J (2017) 0.75
Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics (2003) 17.92
A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Mol Psychiatry (2007) 6.72
Medical genetics: a marker for Stevens-Johnson syndrome. Nature (2004) 5.43
Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am (2003) 5.05
Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry (2006) 3.66
Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am J Psychiatry (2007) 2.87
Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet (2006) 2.55
Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. Am J Psychiatry (2007) 1.88
The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. Biol Psychiatry (2008) 1.86
A genomewide association study of response to lithium for prevention of recurrence in bipolar disorder. Am J Psychiatry (2009) 1.84
Pharmacogenetics of psychotropic drug response. Am J Psychiatry (2004) 1.61
Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. Arch Gen Psychiatry (2007) 1.53
Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics J (2004) 1.51
Is response to prophylactic lithium a familial trait? J Clin Psychiatry (2002) 1.43
Translating pharmacogenomics: challenges on the road to the clinic. PLoS Med (2007) 1.39
Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis. Eur J Hum Genet (2009) 1.38
Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J (2009) 1.35
Measuring depression: comparison and integration of three scales in the GENDEP study. Psychol Med (2007) 1.31
A systematic method for estimating individual responses to treatment with antipsychotics in CATIE. Schizophr Res (2008) 1.30
Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR(*)D study. Neuropsychopharmacology (2008) 1.29
Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology (2002) 1.23
Pharmacogenetics in drug discovery and development: a translational perspective. Nat Rev Drug Discov (2008) 1.23
Prophylactic treatment response in bipolar disorder: results of a naturalistic observation study. J Affect Disord (2007) 1.20
Genomics and the future of pharmacotherapy in psychiatry. Int Rev Psychiatry (2007) 0.95
Pharmacogenetics of antipsychotic-induced weight gain. Psychopharmacology (Berl) (2004) 0.92
Phenotypic spectra of bipolar disorder in responders to lithium versus lamotrigine. Bipolar Disord (2003) 0.90
Pharmacogenomics and the drug discovery pipeline: when should it be implemented? Am J Pharmacogenomics (2005) 0.88
Rapid cycling bipolar disorders in primary and tertiary care treated patients. Bipolar Disord (2008) 0.80
Application of pharmacogenetics to psychotic disorders: the first consensus conference. The Consensus Group for Outcome Measures in Psychoses for Pharmacological Studies. Schizophr Res (1999) 0.78
Large recurrent microdeletions associated with schizophrenia. Nature (2008) 20.25
Assessing the impact of population stratification on genetic association studies. Nat Genet (2004) 16.28
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature (2012) 16.13
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet (2009) 14.86
New models of collaboration in genome-wide association studies: the Genetic Association Information Network. Nat Genet (2007) 13.76
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat Genet (2008) 10.52
Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat Genet (2008) 10.49
Common variants conferring risk of schizophrenia. Nature (2009) 10.37
Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat Neurosci (2009) 10.17
Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature (2010) 9.81
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
The organization of the human cerebral cortex estimated by intrinsic functional connectivity. J Neurophysiol (2011) 8.79
Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet (2009) 8.11
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet (2013) 8.02
Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry (2005) 7.94
Functional organization of the transcriptome in human brain. Nat Neurosci (2008) 7.02
A mega-analysis of genome-wide association studies for major depressive disorder. Mol Psychiatry (2012) 6.34
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet (2008) 6.24
Microduplications of 16p11.2 are associated with schizophrenia. Nat Genet (2009) 6.13
Perioperative fluid therapy with tetrastarch and gelatin in cardiac surgery--a prospective sequential analysis*. Crit Care Med (2013) 5.88
National trends in the outpatient diagnosis and treatment of bipolar disorder in youth. Arch Gen Psychiatry (2007) 5.49
Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry (2002) 5.25
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord (2005) 4.94
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother (2013) 4.80
Disruption of the neurexin 1 gene is associated with schizophrenia. Hum Mol Genet (2008) 4.78
Genomewide association studies: history, rationale, and prospects for psychiatric disorders. Am J Psychiatry (2009) 4.74
Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet (2007) 4.54
Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet (2009) 4.38
International Society for Bipolar Disorders Task Force on Suicide: meta-analyses and meta-regression of correlates of suicide attempts and suicide deaths in bipolar disorder. Bipolar Disord (2014) 4.10
Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet (2004) 3.91
Multiple independent loci at chromosome 15q25.1 affect smoking quantity: a meta-analysis and comparison with lung cancer and COPD. PLoS Genet (2010) 3.91
Identification of common variants associated with human hippocampal and intracranial volumes. Nat Genet (2012) 3.73
The developmental trajectory of bipolar disorder. Br J Psychiatry (2013) 3.69
Pleiotropy in complex traits: challenges and strategies. Nat Rev Genet (2013) 3.65
Key susceptibility locus for nonsyndromic cleft lip with or without cleft palate on chromosome 8q24. Nat Genet (2009) 3.58
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord (2009) 3.56
Duplications of the neuropeptide receptor gene VIPR2 confer significant risk for schizophrenia. Nature (2011) 3.51
Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. J Clin Psychiatry (2015) 3.46
Abnormal behavior in a chromosome-engineered mouse model for human 15q11-13 duplication seen in autism. Cell (2009) 3.45
Hippocampal plasticity in response to exercise in schizophrenia. Arch Gen Psychiatry (2010) 3.42
National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry (2006) 3.38
Course of illness, hippocampal function, and hippocampal volume in major depression. Proc Natl Acad Sci U S A (2003) 3.29
Bipolar disorder. Lancet (2002) 3.26
Combined analysis from eleven linkage studies of bipolar disorder provides strong evidence of susceptibility loci on chromosomes 6q and 8q. Am J Hum Genet (2005) 3.24
Implementation of an evidence-based "standard operating procedure" and outcome in septic shock. Crit Care Med (2006) 3.18
Chronic and treatment resistant depression: diagnosis and stepwise therapy. Dtsch Arztebl Int (2014) 3.14
Meta-analysis of genome-wide association studies of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry (2010) 3.13
Genome-wide association study of alcohol dependence. Arch Gen Psychiatry (2009) 3.08
High frequencies of de novo CNVs in bipolar disorder and schizophrenia. Neuron (2011) 3.08
Bacterial infection causes stress-induced memory dysfunction in mice. Gut (2010) 3.06
Genome scan meta-analysis of schizophrenia and bipolar disorder, part III: Bipolar disorder. Am J Hum Genet (2003) 3.02
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord (2012) 3.01
Nutritional biochemistry: A new redox-cofactor vitamin for mammals. Nature (2003) 2.97
Treatment of depressive disorders. Dtsch Arztebl Int (2008) 2.96
Genome-wide association study identifies two susceptibility loci for nonsyndromic cleft lip with or without cleft palate. Nat Genet (2009) 2.93
Neural mechanisms of a genome-wide supported psychosis variant. Science (2009) 2.88
Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am J Psychiatry (2007) 2.87
Telomere shortening and mood disorders: preliminary support for a chronic stress model of accelerated aging. Biol Psychiatry (2006) 2.85
Parental diagnoses in youth with narrow phenotype bipolar disorder or severe mood dysregulation. Am J Psychiatry (2007) 2.83